Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8453413 | Leukemia Research | 2017 | 6 Pages |
Abstract
These data show that pre allo-SCT molecular MRD evaluation using WT1 expression is a powerful predictor of post allo-SCT outcomes in AML undergoing SCT in cCR. Patients with both cCR and MRD-WT1 negativity before SCT have a very good outcome with lower RR and improved OS. The pre allo-SCT MRD-WT1 stratification in AML is a valuable tool to identify patients at high risk of post-SCT relapse, and can influence conditioning regimen intensification and/or post-SCT preemptive strategies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anna Candoni, Federico De Marchi, Maria Elena Zannier, Davide Lazzarotto, Carla Filì, Maria Vittoria Dubbini, Nicholas Rabassi, Eleonora Toffoletti, Bonnie W. Lau, Renato Fanin,